Special Issue "Drug Insight: Vitamin D and Its Analogs"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 28 February 2022.

Special Issue Editor

Dr. Julia O. Fedotova
E-Mail Website
Guest Editor
1. Laboratory of Neuroendocrinology, I.P. Pavlov Institute of Physiology, Russian Academy of Sciences, 6 Emb. Makarova, 199034 St. Petersburg, Russia
2. International Research Centre "Biotechnologies of the Third Millennium", ITMO University, 9 Lomonosova Str., 191002 St. Petersburg, Russia
Interests: vitamin D; menopausa; estrogens; testosterone; depression, anxiety; schizophrenia; memory; behavior; cognitive disorders; Alzheimer’s disease; neuropsychopharmacology; neuroimmunology; pharmacocorrection; hormonal disorders; biotechnology; functional food supplements

Special Issue Information

Dear Colleagues,

Vitamin D is an exciting topic for many issues in the scientific research. The first evidence of a compound D formation in the course of biological evolution dates back to probably more than 500 million years ago, although this dating may be questionable. It is surely one of the first hormones, or even the very first one, that was produced on Earth. Many preclinical and clinical studies have strongly suggested that hormone D plays several physiological key roles in different areas. However, many questions still remain and will likely fuel ongoing investigation and debate. These questions will likely keep the story open on the pleiotropic effects of Vitamin D for the future.

This Special Issue of Pharmaceuticals on “Vitamin D and its Analogs” will include both experimental/clinical articles and reviews focused on the most recent advances in the research into Vitamin D and its analogs used in medicine, highlighting their beneficial effects in different disorders. The major focus will be on Vitamin D and its analogs’ effects on different diseases, including studies concerning their pathophysiological and molecular mechanisms. Special attention will be addressed to the design, synthesis, characterization, and preclinical studies of novel Vitamin D analogs.

With the aim of offering a dedicated forum open to all scientists engaged in this interdisciplinary research field, we particularly welcome contributions dealing with the following:

  • The beneficial effects of Vitamin D and its analogs as therapeutic tools for the treatment of neuroendocrinological and neuroimmunological impairments;
  • Vitamin D and its analogs as supplementations (design, synthesis, characterization, preclinical studies, clinical trials, etc.) for the treatment of different disorders, particularly with applications in anticancer treatment, reproduction, cognition, psychotropics, neurology, autoimmunity, and for the treatment of cardiovascular disorders, metabolic and hormonal diseases, etc.;
  • The beneficial effects of Vitamin D and its analogs as neuroprotective agents;

Antioxidant, antihypoxic, and anti-aging effects of Vitamin D and its analogs in the preclinical and clinical studies.

Among others research topics, the Special issue will provide a scientific view on the potential role of vitamin D in the treatment of the SARS-CoV-2 virus/COVID-19 disease:

  • Studies of the mechanism of antiviral action of Vitamin D, with a special focus on the its molecular and biochemical mechanisms in SARS-CoV-2 virus/COVID-19 disease;
  • Studies on the different treatments with Vitamin D in the complex therapy of COVID-19.

Dr. Julia O. Fedotova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vitamin D
  • vitamin D analogs
  • endocrine system
  • immune system
  • cognitive disorders
  • affective-related disorders
  • neurological disorders
  • metabolic disorders
  • reproductive and hormonal disorders
  • neuroprotection
  • anti-aging
  • antioxidants
  • SARS-CoV-2
  • COVID-19

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study
Pharmaceuticals 2021, 14(12), 1222; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14121222 - 25 Nov 2021
Viewed by 469
Abstract
Testicular torsion (TT) is the most common urological emergency in children and young adults that can lead to infertility in many cases. The ischemia-reperfusion (IR) injury due to TT has been implicated in the pathogenesis of testicular damage. The main pathological mechanisms of [...] Read more.
Testicular torsion (TT) is the most common urological emergency in children and young adults that can lead to infertility in many cases. The ischemia-reperfusion (IR) injury due to TT has been implicated in the pathogenesis of testicular damage. The main pathological mechanisms of contralateral injury after ipsilateral TT are not fully understood. In the presented study, we investigated the molecular and microscopic basis of ipsilateral and contralateral testicular injury following ipsilateral testicular torsion detorsion (T/D) and explored the possible protective role of vitamin D3. The biochemical analysis indicated that IR injury following T/D significantly decreased the activity of testicular glutathione peroxidase (GPx) enzyme, level of serum testosterone, serum inhibin B, and expression of testicular miRNA145, while increased the activity of testicular myeloperoxidase (MPO) enzyme, level of testicular malondialdehyde (MDA), level of serum antisperm-antibody (AsAb), and expression of ADAM-17. The histological and semen analysis revealed that torsion of the testis caused damages on different tissues in testis. Interestingly, administration of vitamin D3 prior to the IR injury reversed the deterioration effect of IR injury on the testicular tissues as indicated by biochemical and histological analysis which revealed normal appearance of the seminiferous tubules with an apparent decrease in collagen fiber deposition in both ipsilateral and contralateral testes. Our results revealed that the protective effect of vitamin D3 treatment could be attributed to target miRNA145 and ADAM17 protein. To further investigate these findings, we performed a detailed molecular modelling study in order to explore the binding affinity of vitamin D3 toward ADAM17 protein. Our results revealed that vitamin D3 has the ability to bind to the active site of ADAM17 protein via a set of hydrophobic and hydrophilic interactions with high docking score. In conclusion, this study highlights the protective pharmacological application of vitamin D3 to ameliorate the damages of testicular T/D on the testicular tissues via targeting miRNA145 and ADAM17 protein. Full article
(This article belongs to the Special Issue Drug Insight: Vitamin D and Its Analogs)
Show Figures

Graphical abstract

Back to TopTop